INOVIO Pharmaceuticals Announces Employee Equity Grant Under Inducement Plan for New Talent Acquisition

INOVIO Pharmaceuticals: Inducement Grant Announcement

INOVIO Pharmaceuticals, Inc. (NASDAQ: INO), a cutting-edge biotechnology company, has recently taken steps to strengthen its talent pool. On December 19, 2025, the firm announced an equity grant made under its Inducement Plan aimed at securing top-notch professionals to further its mission in the DNA medicine sector. The plan is part and parcel of INOVIO’s commitment to developing innovative treatments for HPV-related diseases, various cancers, and infectious ailments.

The Compensation Committee, as per the regulations stipulated in Nasdaq Listing Rule 5635(c)(4), has sanctioned a stock option grant consisting of 24,000 shares of common stock to a new employee. This grant holds significance as it represents INOVIO's strategic approach to incentivize new hires, making them stakeholders in the company. The grant date is set for November 28, 2025, aligning with the company's operational and fiscal strategies.

As for the specifics of the equity award, the stock options come with an exercise price of $2.06, which is reflective of INOVIO's common stock closing value on the grant date. The awarded options are intended to vest incrementally over a three-year timeline. Specifically, one-third of the shares will vest upon reaching each of the first, second, and third anniversaries of the grant date. Importantly, this vesting is contingent upon the employee remaining employed at INOVIO throughout the vesting period, ensuring alignment of long-term interests between the company and its workforce.

INOVIO’s focus on DNA medicines utilizes state-of-the-art technology designed to effectively instruct the body to generate its own defense mechanisms against debilitating diseases. By fostering a national and potentially global influence in health innovation, the company aims to take significant strides toward eradicating diseases that plague societies today.

The new Inducement Plan initiative underlines how INOVIO is strategically maneuvering to build a formidable team that mirrors the company's ambition to create impactful health solutions. Such measures indicate a forward-thinking approach to corporate governance and employee engagement, which are critical for nurturing an atmosphere of innovation.

Through its dedicated efforts, INOVIO is charting a course toward not only enhancing its human capital but also solidifying its position as a leader in biotechnology. As we look ahead, it will be interesting to observe how these equity grants contribute to the company's growth trajectory and its contributions to the fields of health and medicine.

In summation, INOVIO Pharmaceuticals set the stage for innovation and excellence through this new equity grant as they continue striving for scientific advancements that hold the promise of a healthier future for all. For more details about INOVIO's mission and advancements, visit www.inovio.com.